Sorafenib and Cryoablation May Offer Alternative Treatment for Advanced Renal Cell Carcinoma

Patients with advanced renal cell carcinoma who were treated with a combination of sorafenib and cryoablation fared better than those who were treated with sorafenib alone, researchers from Tianjin, China, reported.

Cryoablation has been studied in early-stage renal cell carcinoma, but there have been few reports on its efficacy when combined with sorafenib for treatment of advanced disease, the investigators stated. They undertook the current study to determine whether combined therapy could improve the prognosis in patients with advanced renal cell carcinoma.

The observational study included 156 patients with advanced renal cell carcinoma who were not eligible for surgical treatment. There were 67 patients in the cryoablation and sorafenib group, and 89 patients in the group that received only sorafenib. The researchers compared several factors between the groups—objective response rate, disease control rate, progression-free survival time, overall survival, change in immune function after treatment, adverse events rate, and quality of life.

Analysis revealed that the objective response rate and disease control rate were both significantly higher among patients in the combined treatment group, whereas progression-free survival time and overall survival were longer in the sorafenib only group. Additionally, patients in the combined group had significantly improved immune function-related indicators after treatment, while there was no significant difference in those factors following treatment with sorafenib only. Targeted drug-related adverse event rates did not significantly differ between the combination and sorafenib only groups, the researchers noted.

“Cryoablation combined with sorafenib had superior clinical efficacy compared with sorafenib-only for the treatment of advanced renal cell carcinoma unsuitable for surgical treatment.

Moreover, this combined therapy may enhance the body’s anti-tumor immunity and effectively prolong PFS and OS without compromising patient quality of life, thus representing a new treatment strategy for advanced renal cell carcinoma,” the researchers concluded.

—Lauren LeBano

References

Liu C, Cao F, Xing W, Si T, Yu H, Yang X, Guo Z. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma. Int J Hyperthermia. 2019 Jan 21:1-9.